Issue 45 - The Cancer Letter

Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

Federate the data: NCI produces master plan for the Childhood Cancer Data Initiative

Sharpless: “This is one of the most uncertain budget environments that I think the NCI has ever experienced.”

Cancer groups say Trump administration's drug pricing rule will likely harm patients

How AI uncovers “invisible” socioeconomic risk factors to improve cancer care

In Brief

GRAIL and UK government plan to make Galleri multi-cancer early detection blood test available

Raymond Bergan named deputy director at Fred & Pamela Buffett Cancer Center

Ramsay Camp named chief of surgical oncology at Baylor College of Medicine

IU's Harikrishna Nakshatri receives $1.3 million to improve breast cancer treatment for Black women

FDA and AACR collaborate on Project Livin' Label

Ohio State creates Clara D. Bloomfield Center for leukemia outcomes research

Funding Opportunities

Israel Cancer Research Fund offers 69 cancer research grants

Clinical Roundup

UVA researchers identify gene responsible for metastasis of TNBC

City of Hope initiates phase I study to test its first SARS-CoV-2 investigational vaccine

Drugs & Targets

Danyelza receives FDA approval for treatment of neuroblastoma

Gavreto receives FDA approval for RET-altered thyroid cancers

FDA approves first PSMA-targeted PET imaging drug for in prostate cancer

European Commission approves Opdivo as second-line treatment for unresectable advanced, recurrent or metastatic ESCC

EMA validates tepotinib application for treatment of advanced NSCLC with METex14 skipping alterations

NCI Trials

NCI Trials for December 2020

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login